Linganisha mbinu
Pitia mbinu ulizochagua bega kwa bega; safu zinazotofautiana zinaangaziwa.
| Uchanganuzi wa Ufanisi wa Gharama (CEA)× | Uchambuzi wa Gharama-Faida (CBA)× | |
|---|---|---|
| Nyanja | Uchumi wa Afya | Uchumi wa Afya |
| Familia | Process / pipeline | Process / pipeline |
| Mwaka wa asili≠ | 1984 | 1970s |
| Mwanzilishi≠ | Drummond & Stoddart (Health Economics Research Group, McMaster University) | Boardman, Greenberg, and colleagues (welfare economics) |
| Aina | Method | Method |
| Chanzo asilia≠ | Gold, M. R., Siegel, J. E., Russell, L. B., & Weinstein, M. C. (Eds.). (1996). Cost-Effectiveness in Health and Medicine. New York: Oxford University Press. link ↗ | Boardman, A. E., Greenberg, D. H., Vining, A. R., & Weimer, D. L. (2018). Cost-Benefit Analysis: Concepts and Practice (5th ed.). Cambridge: Cambridge University Press. link ↗ |
| Majina mbadala | CEA, ICER, Incremental Cost-Effectiveness Ratio | CBA, economic appraisal, benefit-cost ratio |
| Zinazohusiana | 5 | 5 |
| Muhtasari≠ | Cost-effectiveness analysis compares the incremental cost per unit of health benefit gained by one intervention relative to a comparator (standard care or best alternative). Developed rigorously in the 1980s by Drummond, Stoddart, and colleagues, CEA is now the standard framework for technology appraisal globally. NICE, HAS, CADTH, and other health technology assessment bodies use CEA to decide which treatments warrant public funding and at what price. | Cost-benefit analysis compares the total monetary value of benefits produced by a program against its total monetary costs, reporting net present value (NPV) or benefit-cost ratio (BCR). Rooted in welfare economics and used extensively in public policy (transportation, environmental, education, health), CBA answers the question: 'Is this program worth doing from a societal perspective?' Unlike cost-effectiveness analysis, CBA monetizes both costs and benefits, enabling comparison across disparate program types. |
| ScholarGateSeti ya data ↗ |
|
|